{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:38:49Z","timestamp":1787063929270,"version":"build-2736575974"},"posted":{"date-parts":[[2026,2,15]]},"group-title":"Biochemistry","reference-count":49,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Proteolysis-targeting chimeras (PROTACs) represent a transformative therapeutic modality, yet the viability of covalent PROTACs remains debated, as irreversible binding seemingly contradicts the catalytic mechanism central to their function. Here, we develop and characterize PSIRC3, a highly potent covalent PROTAC for Bruton\u2019s tyrosine kinase (BTK) that addresses this ambiguity. PSIRC3 induces potent and selective BTK degradation with a sub-nanomolar DC\n                  <jats:sub>50<\/jats:sub>\n                  of 0.75 nM and a D\n                  <jats:sub>max<\/jats:sub>\n                  greater than 85%, while its non-covalent counterpart is completely inactive. This degradation activity is strictly dependent on covalent bond formation with the Cys481 residue, as evidenced by a total loss of efficacy against the C481S BTK mutant. PSIRC3 acts with remarkable speed, achieving maximum BTK degradation within 30 minutes, a kinetic profile linked to rapid cell permeation and efficient ternary complex formation.\n                  <jats:italic>In vivo<\/jats:italic>\n                  , a single administration of PSIRC3 leads to substantial BTK degradation in both PBMCs (&gt;80%) and splenocytes (&gt;50%). Computational modeling, parameterized with experimental data, reveals that degradation efficacy is governed by a delicate balance between E3 ligase and target protein affinities. Specifically, excessively high E3 affinity is detrimental by inducing a hook effect, while higher target affinity is generally beneficial. Our findings provide strong evidence that covalent engagement can drive potent and selective protein degradation, challenging the prevailing notion that catalytic turnover is indispensable for PROTAC efficacy. This work establishes a new benchmark for covalent degraders and opens new avenues for targeting previously intractable proteins.\n                <\/jats:p>","DOI":"10.64898\/2026.02.14.705950","type":"posted-content","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T03:10:13Z","timestamp":1771211413000},"source":"Crossref","is-referenced-by-count":2,"title":["Sub-stoichiometric Degradation is Dispensable for Potent PROTACs: A Case Study for Irreversible Covalent BTK Degraders"],"prefix":"10.64898","author":[{"given":"Ran","family":"Cheng","sequence":"first","affiliation":[{"name":"The Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States"},{"name":"Center for NextGen Therapeutics, Baylor College of Medicine, Houston, Texas 77030, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanfeng","family":"Lin","sequence":"additional","affiliation":[{"name":"The Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States"},{"name":"Center for NextGen Therapeutics, Baylor College of Medicine, Houston, Texas 77030, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[{"name":"The Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States"},{"name":"Center for NextGen Therapeutics, Baylor College of Medicine, Houston, Texas 77030, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrilekha","family":"Misra","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Qi","sequence":"additional","affiliation":[{"name":"The Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States"},{"name":"Center for NextGen Therapeutics, Baylor College of Medicine, Houston, Texas 77030, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-7919","authenticated-orcid":false,"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"The Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States"},{"name":"Center for NextGen Therapeutics, Baylor College of Medicine, Houston, Texas 77030, United States"},{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026021807500418000_2026.02.14.705950v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2019.01.002"},{"key":"2026021807500418000_2026.02.14.705950v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.211"},{"key":"2026021807500418000_2026.02.14.705950v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2017.09.009"},{"key":"2026021807500418000_2026.02.14.705950v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"2026021807500418000_2026.02.14.705950v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55006-2"},{"key":"2026021807500418000_2026.02.14.705950v1.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.141230798"},{"key":"2026021807500418000_2026.02.14.705950v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1858"},{"issue":"9","key":"2026021807500418000_2026.02.14.705950v1.8","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1039\/D1MD00191D","article-title":"Covalent PROTACs: the best of both worlds?","volume":"12","year":"2021","journal-title":"RSC Med Chem. RSC"},{"issue":"4","key":"2026021807500418000_2026.02.14.705950v1.9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/med.22101","article-title":"Unleashing the Power of Covalent Drugs for Protein Degradation","volume":"45","year":"2025","journal-title":"Medicinal Research Reviews"},{"issue":"2","key":"2026021807500418000_2026.02.14.705950v1.10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/acs.chemrev.4c00745","article-title":"Targeted Covalent Modification Strategies for Drugging the Undruggable Targets","volume":"125","year":"2025","journal-title":"Chem Rev. American Chemical Society"},{"key":"2026021807500418000_2026.02.14.705950v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/nature18002"},{"key":"2026021807500418000_2026.02.14.705950v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-00778-3"},{"key":"2026021807500418000_2026.02.14.705950v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.001"},{"key":"2026021807500418000_2026.02.14.705950v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/nature09472"},{"key":"2026021807500418000_2026.02.14.705950v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-024-01821-z"},{"key":"2026021807500418000_2026.02.14.705950v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0279-5"},{"key":"2026021807500418000_2026.02.14.705950v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-019-0351-5"},{"issue":"7","key":"2026021807500418000_2026.02.14.705950v1.18","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1021\/acscentsci.4c00286","article-title":"DCAF16-Based Covalent Handle for the Rational Design of Monovalent Degraders","volume":"10","year":"2024","journal-title":"ACS Cent Sci. American Chemical Society"},{"key":"2026021807500418000_2026.02.14.705950v1.19","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.8b01083"},{"key":"2026021807500418000_2026.02.14.705950v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00542-z"},{"key":"2026021807500418000_2026.02.14.705950v1.21","doi-asserted-by":"crossref","unstructured":"Hassan MM , Li YD , Ma MW , Teng M , Byun WS , Puvar K , Lumpkin R , Sandoval B , Rutter JC , Jin CY , Wang MY , Xu S , Schmoker AM , Cheong H , Groendyke BJ , Qi J , Fischer ES , Ebert BL , Gray NS . Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues. European Journal of Medicinal Chemistry. 2024 Dec 5;279:116904. PMCID: PMC11960843","DOI":"10.1016\/j.ejmech.2024.116904"},{"key":"2026021807500418000_2026.02.14.705950v1.22","unstructured":"Zhuang Z , Byun WS , Kozicka Z , Dwyer BG , Donovan KA , Jiang Z , Jones HM , Abeja DM , Nix MN , Zhong J , S\u0142abicki M , Fischer ES , Ebert BL , Gray NS . Discovery of electrophilic degraders that exploit SNAr chemistry [Internet]. bioRxiv; 2024 [cited 2025 Feb 13]. p. 2024.09.25.615094. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2024.09.25.615094v1 PMCID: PMC11463635"},{"key":"2026021807500418000_2026.02.14.705950v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-024-01668-4"},{"key":"2026021807500418000_2026.02.14.705950v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-024-01660-y"},{"issue":"38","key":"2026021807500418000_2026.02.14.705950v1.25","first-page":"e202508427","article-title":"Rational design of CDK12\/13 and BRD4 molecular glue degraders. Angew Chem (Int Ed","volume":"64","year":"2025","journal-title":"Engl"},{"key":"2026021807500418000_2026.02.14.705950v1.26","doi-asserted-by":"publisher","DOI":"10.1039\/d2cs00362g"},{"key":"2026021807500418000_2026.02.14.705950v1.27","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.4c00570"},{"issue":"1","key":"2026021807500418000_2026.02.14.705950v1.28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","year":"2024","journal-title":"Sig Transduct Target Ther"},{"issue":"5","key":"2026021807500418000_2026.02.14.705950v1.29","first-page":"e202417272","volume-title":"Angew Chem","volume":"64","year":"2025"},{"key":"2026021807500418000_2026.02.14.705950v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2021.03.005"},{"issue":"10","key":"2026021807500418000_2026.02.14.705950v1.31","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1039\/C9CC08238G","article-title":"Protein degradation through covalent inhibitor-based PROTACs","volume":"56","year":"2020","journal-title":"Chem Commun"},{"issue":"1","key":"2026021807500418000_2026.02.14.705950v1.32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring Targeted Degradation Strategy for Oncogenic KRASG12C","volume":"27","year":"2020","journal-title":"Cell Chemical Biology"},{"issue":"8","key":"2026021807500418000_2026.02.14.705950v1.33","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs","volume":"6","year":"2020","journal-title":"ACS Cent Sci. American Chemical Society"},{"key":"2026021807500418000_2026.02.14.705950v1.34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"issue":"1","key":"2026021807500418000_2026.02.14.705950v1.35","first-page":"8373","volume-title":"Nat Commun","volume":"16","year":"2025"},{"key":"2026021807500418000_2026.02.14.705950v1.36","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.8b01094"},{"key":"2026021807500418000_2026.02.14.705950v1.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17997-6"},{"key":"2026021807500418000_2026.02.14.705950v1.38","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.9b13907"},{"key":"2026021807500418000_2026.02.14.705950v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36738-z"},{"issue":"8","key":"2026021807500418000_2026.02.14.705950v1.40","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/acschembio.5b00442","article-title":"HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins","volume":"10","year":"2015","journal-title":"ACS Chem Biol. American Chemical Society"},{"issue":"5","key":"2026021807500418000_2026.02.14.705950v1.41","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acschembio.8b01016","article-title":"Rapid and Reversible Knockdown of Endogenously Tagged Endosomal Proteins via an Optimized HaloPROTAC Degrader","volume":"14","year":"2019","journal-title":"ACS Chem Biol. American Chemical Society"},{"key":"2026021807500418000_2026.02.14.705950v1.42","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0988-z"},{"key":"2026021807500418000_2026.02.14.705950v1.43","doi-asserted-by":"crossref","unstructured":"Yu X , Guo WH , Lin H , Cheng R , Monroy EY , Jin F , Ding L , Lu D , Qi X , Wang MC , Wang J . Discovery of a potent BTK and IKZF1\/3 triple degrader through reversible covalent BTK PROTAC development. Current Research in Chemical Biology. 2022;2:100029.","DOI":"10.1016\/j.crchbi.2022.100029"},{"issue":"8","key":"2026021807500418000_2026.02.14.705950v1.44","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/acsmedchemlett.5c00171","article-title":"One Tracer, Dual Platforms: Unlocking Versatility of Fluorescent Probes in TR-FRET and NanoBRET Target Engagement Assays","volume":"16","year":"2025","journal-title":"ACS Med Chem Lett. American Chemical Society"},{"issue":"4","key":"2026021807500418000_2026.02.14.705950v1.45","first-page":"2321","article-title":"Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton\u2019s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies","volume":"67","year":"2024","journal-title":"J Med Chem. American Chemical Society"},{"issue":"16","key":"2026021807500418000_2026.02.14.705950v1.46","first-page":"TPS5115","article-title":"An oral prostate cancer RIPTAC therapeutic in phase 1 for metastatic castrate resistant prostate cancer (mCRPC)","volume":"43","year":"2025","journal-title":"J Clin Oncol. Wolters Kluwer"},{"key":"2026021807500418000_2026.02.14.705950v1.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2024.07.005"},{"key":"2026021807500418000_2026.02.14.705950v1.48","doi-asserted-by":"crossref","unstructured":"Bulldan A , Zheng M , Meyners C , Purder P , Krieger J , Dreizler J , Geiger TM , Repity M , Lein MH , Quist-L\u00f8kken I , Tewes N , Schwalm M , Schlesiger S , Moniot S , Knapp S , Hartung IV , Holien T , Loewer A , Hausch F. Heterobifunctional Protein Binders Enable Cell Type-Specific Killing Through In-cell Enrichment [Internet]. bioRxiv; 2025 [cited 2025 Dec 1]. p. 2025.05.16.654562. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2025.05.16.654562v1","DOI":"10.1101\/2025.05.16.654562"},{"issue":"6659","key":"2026021807500418000_2026.02.14.705950v1.49","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","year":"2023","journal-title":"Science. American Association for the Advancement of Science"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.02.14.705950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:50:21Z","timestamp":1771429821000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.02.14.705950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":49,"URL":"https:\/\/doi.org\/10.64898\/2026.02.14.705950","relation":{},"subject":[],"published":{"date-parts":[[2026,2,15]]},"subtype":"preprint"}}